TY - JOUR
T1 - Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD
T2 - MyIBDcoach
AU - de Jong, Marin
AU - van der Meulen-de Jong, Andrea
AU - Romberg-Camps, Marielle
AU - Degens, Juliette
AU - Becx, Marco
AU - Markus, Tineke
AU - Tomlow, Henny
AU - Cilissen, Mia
AU - Ipenburg, Nienke
AU - Verwey, Marthe
AU - Colautti-Duijsens, Laurence
AU - Hameeteman, Wim
AU - Masclee, Ad
AU - Jonkers, Daisy
AU - Pierik, Marieke
PY - 2017/4
Y1 - 2017/4
N2 - Background: Tight control of disease activity, medication side effects, and adherence are crucial to prevent disease complications and improve quality of life in patients with inflammatory bowel disease (IBD). The chronic nature and increasing incidence of IBD demand health care innovations to guarantee future high-quality care. Previous research proved that integrated care by telemedicine can improve outcomes of chronic diseases. Currently available IBD telemedicine tools focus on specific patient subgroups. Therefore, we aimed to (1) develop a telemedicine system suitable for all patients with IBD in everyday practice and (2) to test this system's feasibility.Methods: With a structured iterative process between patients, dietitians, IBD nurse-specialists, and gastroenterologists, myIBDcoach was developed. During 3 months, myIBDcoach's feasibility was tested by 30 consecutive outpatients with IBD of 3 hospitals. Thereafter, patients and health care providers completed a questionnaire covering satisfaction, accessibility, and experiences with myIBDcoach.Results: MyIBDcoach enables continuous home-monitoring of patients with IBD and optimizes disease knowledge and communication between patients and health care providers. Besides disease activity, medication adherence, and side effects, myIBDcoach monitors malnutrition, smoking, quality of life, fatigue, life-events, work participation, stress, and anxiety and depression and provides e-learnings for patient empowerment. Patients graded the system with a mean of 7.8 of 10, and 93% would recommend myIBDcoach to other patients.Conclusions: We developed myIBDcoach, which enables integrated care for all patients with IBD, regardless of disease severity or medication use. The feasibility study showed high satisfaction and compliance of patients and health care providers. To study myIBDcoach's efficacy, a multicenter randomized controlled trial has been initiated.
AB - Background: Tight control of disease activity, medication side effects, and adherence are crucial to prevent disease complications and improve quality of life in patients with inflammatory bowel disease (IBD). The chronic nature and increasing incidence of IBD demand health care innovations to guarantee future high-quality care. Previous research proved that integrated care by telemedicine can improve outcomes of chronic diseases. Currently available IBD telemedicine tools focus on specific patient subgroups. Therefore, we aimed to (1) develop a telemedicine system suitable for all patients with IBD in everyday practice and (2) to test this system's feasibility.Methods: With a structured iterative process between patients, dietitians, IBD nurse-specialists, and gastroenterologists, myIBDcoach was developed. During 3 months, myIBDcoach's feasibility was tested by 30 consecutive outpatients with IBD of 3 hospitals. Thereafter, patients and health care providers completed a questionnaire covering satisfaction, accessibility, and experiences with myIBDcoach.Results: MyIBDcoach enables continuous home-monitoring of patients with IBD and optimizes disease knowledge and communication between patients and health care providers. Besides disease activity, medication adherence, and side effects, myIBDcoach monitors malnutrition, smoking, quality of life, fatigue, life-events, work participation, stress, and anxiety and depression and provides e-learnings for patient empowerment. Patients graded the system with a mean of 7.8 of 10, and 93% would recommend myIBDcoach to other patients.Conclusions: We developed myIBDcoach, which enables integrated care for all patients with IBD, regardless of disease severity or medication use. The feasibility study showed high satisfaction and compliance of patients and health care providers. To study myIBDcoach's efficacy, a multicenter randomized controlled trial has been initiated.
KW - telemedicine
KW - inflammatory bowel disease
KW - patient-reported outcome measure
KW - INFLAMMATORY-BOWEL-DISEASE
KW - QUALITY-OF-LIFE
KW - ULCERATIVE-COLITIS
KW - HOME TELEMANAGEMENT
KW - COST-EFFECTIVENESS
KW - ENDOSCOPIC REMISSION
KW - CLINICAL INDEXES
KW - CONTROLLED-TRIAL
KW - CROHNS-DISEASE
KW - VALIDITY
U2 - 10.1097/MIB.0000000000001034
DO - 10.1097/MIB.0000000000001034
M3 - Article
SN - 1078-0998
VL - 23
SP - 485
EP - 493
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 4
ER -